Search Bills

address transparency in prescription drug pricing.

SB 163 updates South Dakota's prescription drug pricing transparency law by clarifying which organizations must follow the transparency rules—including nonprofits, health insurers, employers, and labor unions that provide health coverage to state residents. The bill also refines definitions of key terms like "generic drug" and "labeler" to ensure the law applies consistently across the state's health coverage system.

provide for the redistribution of donated prescription drugs and medical supplies.

This bill creates a new program allowing licensed pharmacies in South Dakota to accept donations of unused prescription drugs and medical supplies, provided the items are in original sealed packaging and won't expire for at least six months. Donated drugs and supplies must be inspected by a licensed pharmacist before being dispensed to patients, and pharmacies must register with the State Board of Pharmacy to participate in the program. The bill prohibits donations of controlled substances and any medications showing signs of tampering or deterioration.

expand the ability for patients to seek investigational drugs, biological products, or devices.

HB 1228 expands access to experimental drugs, biological products, and devices for patients with advanced or serious illnesses by allowing them to try investigational treatments that have completed early safety testing but haven't yet received FDA approval. The bill defines "eligible patients" as those with progressive conditions like advanced illness or serious illness (involving extreme pain or permanent disability) who have exhausted standard treatment options. This creates a pathway for terminally ill or severely ill South Dakotans to seek access to experimental treatments outside of traditional clinical trials.

allow certain medical professionals to dispense ivermectin to persons.

HB 1267 allows certain medical professionals—beyond just physicians—to dispense ivermectin directly to patients without requiring a prescription from a doctor. The bill expands who can distribute this medication by amending the state's pharmacy and medical practice laws to permit qualified healthcare providers to provide ivermectin to people seeking it.

add nabiximols as a Schedule III controlled substance.

SB 113 adds nabiximols (a cannabis-based medication) to South Dakota's list of Schedule III controlled substances, making it a regulated but less restricted drug classification than Schedule I or II. This change would allow the drug to be prescribed by doctors under specific conditions while maintaining state control over its distribution and use.